


2024 Milestones



**Regional
Revolving
Funds**

More than
800 million USD
in total procurement for 2024



This was our year



New Credit Line

process to integrate demand planning with credit allocation cycles and expedite approval workflows

New Priorities

for the Funds: Regional production, supply agreements for rapid response, and a strategic stockpile of medicines.



The RRF

Member State Portal

has become the tool for planning the demand for vaccines, and Member States are increasingly using it for essential medicines and other supplies.



+10% in USD procured

through the RRF compared to 2023.



Countries accessed more than

224M vaccine doses

41M syringes and safety boxes

+10M diagnostic tests

+5M annual treatments

among other investments in immunoglobulins, cold chain, and vector control supplies.

Broader Access





+30 medicines for pediatric cancer

moving forward with the goals of the Global Platform for Access to Childhood Cancer Medicines, as well as **increasing the availability of medicines for Member States.**





High Price Medicines

included in the RRF portfolio, to enhance availability, foster affordability, and support regional production of quality therapeutics.





New Vaccines

included such as RSV, Hexavalent, HPV-9 and PCV-20.





Telehealth Packages

integrated into RRF to advance access to digital healthcare across the Americas.





32 New Antivenoms

incorporated into the RRF portfolio to ensure access to quality antidotes, with snakebite-related clinical guidance.



Savings & Optimization





Locally produced vaccines

State-of-the-art PCV-20 produced in Argentina

With significant benefits such as:

- Produced within the region with export potential
- Programmatic benefits of them being available in pre-filled syringes, suitable for both children and adults, and manufactured with state-of-the-art technology.







Better Prices

compared to fragmented procurement, **for diabetes and cancer key medicines**

Diabetes



Cancer





Better Prices

New affordable options for HPV, Meningococcal, and Rotavirus vaccines were added to the portfolio, which **helps national immunization programs to save and potentially augment coverage**





Cold Chain optimization

in countries like Ecuador and Nicaragua has resulted in significant cost savings, **enabling the reallocation of resources toward critical health investments.**

In Ecuador, these savings supported the acquisition of essential cold chain cargo trucks, and other technologies to advance the sustainable readiness of the Global Platform for Access to Childhood Cancer Medicines initiative.



Strategic Initiatives





Strengthening national pharmaceutical supply chains

for HIV, TB, and Malaria with Global Fund support, including QuantMET and QuantTB implementation; as well as **several monitoring exercises that assessed antiretroviral (ARV) stock status**, analyzing requisitions and purchase orders to identify supply risks.

Our proactive mitigation measures **led to a 27% reduction in Risk Situations** in four countries in Central America

Stockouts probability fell from

10.6%
2023



2.1%
2024



Medical Equipment and Diagnostics

Special Projects developed in Ecuador, Nicaragua, and Cuba to support the attention in Primary Health Care, maternal and neonatal health, pandemic preparedness, and emergency response, and reinforce laboratory capacity in the region.

The RRF also support the diagnostics and rapid test procurement in the region, with over 15 countries procuring more than 10 million tests and equipment to support Disease Elimination Initiative.

Medical Equipment procured

**\$25M
USD**

2023

**\$50M
USD**

2024

Diagnostic Tests procured

**6M
tests**

2023

**10M
tests**

2024



Africa CDC and EMRO

Fostering partnerships to share knowledge and expertise to improve access to health technologies via technical cooperation and pooled procurement.



Thanks!

This would not have been possible without the constant support and joint work with other departments and country offices. We are always grateful to you for your collaboration and input.

Our Member States are the reason for continuing to advance our shared goals.

